Spectrum has a broad and diversified portfolio of proprietary drugs in various stages of development with a focus on oncology.
This includes promising late-stage as well as early-stage drug candidates with unique formulations and mechanisms of action. These potential products address the needs of seriously ill patients, such as new treatment regimens for refractory disease, and rare forms of lung cancer. Several of these development products may have blockbuster potential.
For detailed information regarding these drugs, please select from the links below: